|
Post-diagnostic aspirin exposure
|
Breast cancer-specific deaths n (%)
|
Controls n (%)
|
Unadjusted OR (95% CI)
|
P
|
AdjustedaOR (95% CI)
|
P
|
Additionally adjustedbfor stage and grade OR (95% CI)
|
P
|
|---|
|
No. prescriptions low dose
| | | | | | |
|
0
|
1,173 (81.7)
|
4,641 (81.5)
|
1.00
| |
1.00
| |
1.00
| |
|
1 or more
|
262 (18.3)
|
1,056 (18.5)
|
0.98 (0.83, 1.15)
|
0.77
|
0.98 (0.81, 1.20)
|
0.86
|
1.00 (0.71, 1.41)
|
0.99
|
|
No. prescriptions low dose
| | | | | | |
|
0
|
1,173 (81.7)
|
4,641 (81.5)
|
1.00
| |
1.00
| |
1.00
| |
|
1 to 11
|
117 (8.2)
|
525 (9.2)
|
0.88 (0.71, 1.09)
|
0.25
|
0.90 (0.71, 1.16)
|
0.42
|
0.80 (0.52, 1.24)
|
0.32
|
|
12 or more
|
145 (10.1)
|
531 (9.3)
|
1.08 (0.87, 1.33)
|
0.48
|
1.08 (0.84, 1.39)
|
0.57
|
1.28 (0.82, 2.01)
|
0.27
|
|
No. tablets low dose
| | | | | | |
|
0
|
1,173 (81.7)
|
4,641 (81.5)
|
1.00
| |
1.00
| |
1.00
| |
|
1 to 365
|
90 (6.3)
|
385 (6.8)
|
0.93 (0.72, 1.19)
|
0.55
|
1.01 (0.77, 1.33)
|
0.93
|
0.93 (0.57, 1.52)
|
0.78
|
|
366 or more
|
172 (12.0)
|
671 (11.8)
|
1.01 (0.83, 1.22)
|
0.95
|
0.96 (0.76, 1.22)
|
0.76
|
1.05 (0.69, 1.58)
|
0.83
|
|
No. tablets low dose per day
| | | | | | | | |
|
0
|
1,173
|
4,641 (81.5)
|
1.00
| |
1.00
| |
1.00
| |
|
0 to 0.5
|
93 (6.5)
|
370 (6.5)
|
0.99 (0.78, 1.27)
|
0.97
|
1.02 (0.78, 1.34)
|
0.89
|
0.89 (0.56, 1.42)
|
0.63
|
|
>0.5
|
169 (11.8)
|
686 (12.0)
|
0.97 (0.80, 1.17)
|
0.72
|
0.96 (0.76, 1.21)
|
0.73
|
1.10 (0.72, 1.67)
|
0.67
|
|
No prescriptions high dose
| | | | | | | | |
|
0
|
1,415 (98.6)
|
5,642 (99.0)
|
1.00
| |
1.00
| |
1.00
| |
|
1 or more
|
20 (1.4)
|
55 (1.0)
|
1.47 (0.87, 2.46)
|
0.15
|
1.15 (0.65, 2.04)
|
0.62
|
1.11 (0.31, 4.04)
|
0.87
|
- aModel includes chemotherapy within six months of diagnosis, radiotherapy within six months, tamoxifen (post diagnosis, during exposure period), aromatase inhibitors (post diagnosis, during exposure period), comorbidities (pre-diagnosis or during exposure period, including myocardial infarction, cerebrovascular disease, congestive heart disease, chronic pulmonary disease, peripheral vascular disease, peptic ulcer disease and diabetes), other medication exposure (post diagnosis, during exposure period, including statins, beta-blockers, ACE inhibitors, ARBs and metfomin) and smoking (pre-diagnosis, with missing included as a category).
- bAdjusted model additionally includes stage and grade, restricted to 574 cases and 2,268 controls with available data.
